DaVita Inc. (NYSE:DVA) Stock Has Consensus Price Target of $235.86

DaVita Inc. (NYSE:DVA) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $235.86.

DVA has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Raymond James Financial set a $220.00 price objective on shares of DaVita in a research report on Friday, August 7th. Oppenheimer set a $220.00 target price on shares of DaVita in a research note on Friday, August 7th. TD Cowen lifted their target price on shares of DaVita from $220.00 to $228.00 and gave the company a “buy” rating in a report on Monday, November 2nd. Finally, Barclays dropped their price target on shares of DaVita from $224.00 to $216.00 and set an “equal weight” rating on the stock in a research note on Monday, November 2nd.

DaVita Stock Performance

DaVita stock traded down $3.55 during mid-day trading on Friday, reaching $191.27. 603,670 shares of the company were exchanged, compared to its average volume of 796,165. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49. The firm’s 50-day simple moving average is $182.52 and its two-hundred day simple moving average is $178.61. The firm has a market cap of $12.03 billion, a PE ratio of 14.08, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87.

DaVita (NYSE:DVA) last released its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.57 by $0.25. The business had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.51 earnings per share. As a group, equities research analysts anticipate that DaVita will post 14.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Berkshire Hathaway Inc acquired a new stake in DaVita in the second quarter valued at $6,425,269,000. BlackRock Inc. acquired a new position in DaVita during the second quarter worth about $547,520,000. Bank of America Corp DE purchased a new position in DaVita in the second quarter valued at about $145,057,000. Bank of New York Mellon Corp purchased a new position in DaVita in the second quarter valued at about $101,127,000. Finally, Deutsche Bank AG acquired a new stake in shares of DaVita in the 2nd quarter worth approximately $46,356,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.